Prostate cancer surface targets for car T cell therapy or metastatic prostate cancer in the car T cell era: My kingdom for the target!

Результат исследования: Научные публикации в периодических изданияхобзорная статья

Аннотация

Despite the progress achieved in target, chemo-, and radiotherapy, treatment options for patients with latestage metastatic castration-resistant prostate cancer are presently very limited. Use of dendritic cell-based vaccines exemplified by sipuleucel-T appears is rarely curative and is effective in only a fraction of such patients. Given the success of CAR T cell therapy in the field of B cell malignancies, significant efforts have been made to adapt this powerful technology to the problem of metastatic prostate cancer. Availability of unique prostate cancer surface targets for CAR T cells has thereby become a pressing issue in the field of CAR design. Ideally, such targets should be absent from normal cells or tissues, be present on all prostate cancer cells across all patients, and be indispensable for the survival of cancer cells. In reality, however, none of the prostate cancer-associated surface markers described to date are matching such description. Here, we catalogue the list of tested as well as prospective surface antigens to be used as targets for CAR T cell therapy, and discuss the aspects of their safety and potential efficacy.

Язык оригиналаанглийский
Страницы (с-по)19-28
Число страниц10
ЖурналCellular Therapy and Transplantation
Том8
Номер выпуска4
DOI
СостояниеОпубликовано - 1 ноя 2019

Fingerprint Подробные сведения о темах исследования «Prostate cancer surface targets for car T cell therapy or metastatic prostate cancer in the car T cell era: My kingdom for the target!». Вместе они формируют уникальный семантический отпечаток (fingerprint).

  • Цитировать